Sharp Therapeutics Corp.

Research Sharp Therapeutics Corp. (SHRX) on Bullrun: market cap CAD 27.37M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CAD 27.37M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 6.17M-USD 4.83Mn/an/aUSD 956.60KUSD 1.28M-USD 176.60K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CAD 27.37Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CAD.

About Sharp Therapeutics Corp.

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sharp Therapeutics Corp.'s market cap?

Sharp Therapeutics Corp.'s market capitalization is CAD 27.37M.

What does Sharp Therapeutics Corp. do?

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp.